Autoimmune disease
11 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Rescooped by Ricardo Pujol Borrell from PARP Inhibitors Cancer Review
Scoop.it!

Senescence-associated inflammatory responses: aging and cancer perspectives: Trends in Immunology

Senescence-associated inflammatory responses: aging and cancer perspectives: Trends in Immunology | Autoimmune disease | Scoop.it

Highlights

 

An inflammatory response is one of the hallmarks of cellular senescence.

It serves to both propagate the senescence process and facilitate its clearance.

Senescence–inflammatory response may support tumor proliferation and invasion.

Blocking the response is potentially therapeutic in cancer and aging-related diseases.

This may be achieved by specific anti-inflammatory agents and NSAIDs.

 

Senescent cells, albeit not proliferating, are metabolically and transcriptionally active, thereby capable of affecting their microenvironment, notably via the production of inflammatory mediators. These mediators maintain and propagate the senescence process to neighboring cells, and then recruit immune cells for clearing senescent cells. Among the inflammatory cues are molecules with pronounced tumor-controlling properties, both growth and invasion factors and inhibitory factors, working directly or via recruited immune cells. These senescence–inflammatory effects also prevail within tumors, mediated by the senescent tumor cells and the senescent tumor stroma. Here, we review the course and impact of senescence-associated inflammatory responses in aging and cancer. We propose that controlling senescence-associated inflammation by targeting specific inflammatory mediators may have a beneficial therapeutic effect in treatment of cancer and aging-related diseases.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 14, 2015 12:19 AM

Trends in Immunology

 

Volume 36, Issue 4, April 2015, Pages 217–228

Feature Review Senescence-associated inflammatory responses: aging and cancer perspectivesAudrey Lasry, Yinon Ben-Neriah   doi:10.1016/j.it.2015.02.009

Alejandro Melo-Florián MD's curator insight, April 14, 2015 11:59 PM

More on inflammaging.

Gilbert C FAURE's curator insight, April 18, 2015 4:47 AM

ageing and immunity

Rescooped by Ricardo Pujol Borrell from Immunology Diagnosis
Scoop.it!

5 Things to Consider when Developing Clinical Biomarkers

5 Things to Consider when Developing Clinical Biomarkers | Autoimmune disease | Scoop.it
Developing cellular biomarkers is particularly challenging when it comes to biomarker validation, because flow cytometry has limitations regarding sample stability and multiplexing. Moreover, the development of highly multiplex flow cytometry assays is time-consuming and expanding existing panels can be quite cumbersome. ChipCytometry is a new, imaging based, cytometry technology bridging the gap between biomarker discovery and clinical biomarker validation through flexible “sequential singleple

Via Alfredo Corell
Ricardo Pujol Borrell's insight:

very useful

more...
Alfredo Corell's curator insight, March 5, 2015 6:21 PM

Some guidelines by Zellkraftwerk, the company developing the new called "chipCytometry"